Nuvation Bio Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.5
- Today's High:
- $1.56
- Open Price:
- $1.56
- 52W Low:
- $1.5
- 52W High:
- $2.62
- Prev. Close:
- $1.54
- Volume:
- 365539
Company Statistics
- Market Cap.:
- $360.09 million
- Book Value:
- 2.854
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -9.09%
- Return on Equity TTM:
- -13.72%
Company Profile
Nuvation Bio Inc had its IPO on 2020-08-24 under the ticker symbol NUVB.
The company operates in the Healthcare sector and Biotechnology industry. Nuvation Bio Inc has a staff strength of 54 employees.
Stock update
Shares of Nuvation Bio Inc opened at $1.56 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.5 - $1.56, and closed at $1.5.
This is a -2.6% slip from the previous day's closing price.
A total volume of 365,539 shares were traded at the close of the day’s session.
In the last one week, shares of Nuvation Bio Inc have slipped by -8.54%.
Nuvation Bio Inc's Key Ratios
Nuvation Bio Inc has a market cap of $360.09 million, indicating a price to book ratio of 0.6278 and a price to sales ratio of 0.
In the last 12-months Nuvation Bio Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-98708000. The EBITDA ratio measures Nuvation Bio Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Nuvation Bio Inc’s operating margin was 0% while its return on assets stood at -9.09% with a return of equity of -13.72%.
In Q2, Nuvation Bio Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Nuvation Bio Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.41 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Nuvation Bio Inc’s profitability.
Nuvation Bio Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 2.0042. Its price to sales ratio in the trailing 12-months stood at 0.
Nuvation Bio Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $641.41 million
- Total Liabilities
- $13.41 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $22000
- Dividend Payout Ratio
- 0%
Nuvation Bio Inc ended 2024 with $641.41 million in total assets and $0 in total liabilities. Its intangible assets were valued at $641.41 million while shareholder equity stood at $624.63 million.
Nuvation Bio Inc ended 2024 with $0 in deferred long-term liabilities, $13.41 million in other current liabilities, 938395000.00 in common stock, $-309368000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $50.07 million and cash and short-term investments were $630.90 million. The company’s total short-term debt was $1,283,000 while long-term debt stood at $0.
Nuvation Bio Inc’s total current assets stands at $637.23 million while long-term investments were $0 and short-term investments were $580.84 million. Its net receivables were $2.80 million compared to accounts payable of $2.58 million and inventory worth $0.
In 2024, Nuvation Bio Inc's operating cash flow was $0 while its capital expenditure stood at $22000.
Comparatively, Nuvation Bio Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.5
- 52-Week High
- $2.62
- 52-Week Low
- $1.5
- Analyst Target Price
- $3.93
Nuvation Bio Inc stock is currently trading at $1.5 per share. It touched a 52-week high of $2.62 and a 52-week low of $2.62. Analysts tracking the stock have a 12-month average target price of $3.93.
Its 50-day moving average was $1.74 and 200-day moving average was $1.83 The short ratio stood at 3.99 indicating a short percent outstanding of 0%.
Around 2689.7% of the company’s stock are held by insiders while 6320% are held by institutions.
Frequently Asked Questions About Nuvation Bio Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company’s lead product candidate is NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.